- ¥6000 - 9000
- theramabs
- TM-Ado-00005
- 2026年01月08日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 靶点：
her2
- 克隆性：
多克隆
- 抗体英文名：
Ado-trastuzumab emtansine
- 抗体名：
曲妥珠单抗-美坦新偶联物
- 规格：
5mg
Description
Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 via the stable thioether linker MCC. Trastuzumab is produced by Chinese hamster ovary cells, and DM1-MCC are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody.
Ado-trastuzumab emtansine is supplied at a concentration of 20 mg/mL as a sterile, clear and colorless, preservative-free solution, which contains polysorbate 20 [0.02% (w/v)], sodium succinate (10 mM), and sucrose [6% (w/v)] with a pH of 5.0.
Properties
| Name | Ado-trastuzumab emtansine |
| CAS NO. | 1018448-65-1 |
| Type | Whole antibody |
| Source | humanized (from mouse) |
| Target | HER2 |
| Clone | Monoclone |
| Formula | C6448H9948N1720O2012S44 |
| Molecular Weight | 149 kDa |
| Antibody Form | Purified immunoglobulin |
| Physical Form | Solution |
| Grade Standard | Medicine Grade |
| Place of Origin | China (Mainland) |
| Storage | -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light. |
20 kilogram per year, Minimum order quantity is 1 gram.
Price
Inquiry
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
Detail information about the product please refer the website below:
https://en.wikipedia.org/wiki/Trastuzumab_emtansine
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验AntibodyDrug Conjugate (ADC) Clinical Pipeline: A Review
today. A total of 27 ADC are currently undergoing clinical trials in both hematological malignancies and solid tumor indications. Among them, T-DM1 (trastuzumab emtansine), an ADC comprised of trastuzumab conjugated to DM1, via a non-cleavable linker
S-Adenosyl-L-Homocysteine Hydrolase
The enzymatic activity that catalyzes the reversible hydrolysis of S-adenosyl-L -homocysteine (AdoHcy) to L -homocysteine (Hey) and adenosine (Ado), or, in reverse, the formation of AdoHcy from Hcy and Ado, is known as AdoHcy hydrolase (AHH
Therapeutic Human Monoclonal Antibodies Against Cancer
. There are a number of monoclonal antibodies used in the treatment of malignancies; in fact, three of the top five grossing antibodies (bevacizumab, trastuzumab, and rituximab) are used in oncology Scolnik (mAbs 1:179–184, 2009).
技术资料暂无技术资料 索取技术资料
